Thursday , December 14 2017
Home / Business News

Business News

Daiichi Sankyo and Puma Collaborate with Major Cancer Center in HER2-Mutated Cancer

TOKYO, BASKING RIDGE, N.J. & LOS ANGELES–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc. (Nasdaq: PBYI) have announced a preclinical research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to explore the combination of Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 and Puma Biotechnology’s irreversible pan-HER …

Read More »

Vertex and CRISPR Therapeutics Partner to Develop CTX001 as CRISPR/Cas9 Gene Edited Treatment

BOSTON, CAMBRIDGE, Mass. & ZUG, Switzerland–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies’ previously announced collaboration aimed at the discovery and development of new gene editing treatments …

Read More »

Gilead to Acquire Cell Design Labs for $567 Million

FOSTER CITY, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and its cell therapy subsidiary Kite announced today that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms that will enhance research and development efforts …

Read More »

bluebird bio and TC BioPharm Collaborate to Develop Gamma Delta CAR T Cell Products for Cancer Immunotherapy

CAMBRIDGE, Mass. & EDINBURGH, Scotland–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Scottish immunotherapy company TC BioPharm, Ltd. (TCB) today announced a strategic collaboration and license agreement focused on gamma delta CAR T cells. The companies will work together to advance TC BioPharm’s lead CAR-engineered gamma delta T cell program into clinical …

Read More »

Juno Signs Three Licensing Agreements to Advance its Multiple Myeloma Program with Gamma Secretase Inhibition

SEATTLE–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced three license agreements to advance its program in multiple myeloma using gamma secretase inhibitors (GSIs) in combination with BCMA-directed CAR T cells. Gamma secretase is an enzyme that cleaves a …

Read More »

Genomic Health and Janssen Collaborate to Evaluate Oncotype DX Genomic Prostate Score Test for Potential Drug Development

REDWOOD CITY, Calif., Dec. 6, 2017 /PRNewswire/ — Genomic Health, Inc. (NASDAQ: GHDX) today announced a multi-year research collaboration agreement with Janssen Pharmaceuticals to evaluate the Oncotype DX Genomic Prostate Score™ (GPS™) test for their prostate cancer drug pipeline.  As part of the agreement, Genomic Health will test samples from …

Read More »

CVS Health to Acquire Health Insurer Aetna for $69 Billion

WOONSOCKET, R.I. and HARTFORD, Conn., Dec. 3, 2017 /PRNewswire/ — CVS Health (NYSE: CVS), a company at the forefront of changing the health care landscape, and Aetna (NYSE: AET), one of the nation’s leading diversified health care benefits companies, today announced the execution of a definitive merger agreement under which CVS Health will acquire …

Read More »

bluebird bio Acquires North Carolina Manufacturing Facility and Executes Multiple Global Supply Agreements

CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene and cell therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced it has acquired a 125,000-square foot manufacturing facility in Durham, North Carolina. Once construction and validation is complete, the site …

Read More »

X-Chem and Gilead Enter Drug Discovery Collaboration

WALTHAM, Mass.–(BUSINESS WIRE)–X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Gilead Sciences, Inc. (Gilead). Under the terms of the agreement, X-Chem will screen its proprietary DEXTM libraries, which contain >120 …

Read More »

Genomic Health and Cleveland Diagnostics Partner to Develop and Commercialize New Prostate Cancer Tests

REDWOOD CITY, Calif. and CLEVELAND, Nov. 28, 2017 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX), the world’s leading provider of genomic-based diagnostic tests, and Cleveland Diagnostics, Inc., a biotechnology company focused on developing next-generation diagnostics technology for the detection of cancers, today announced an exclusive licensing agreement to develop and …

Read More »